GoKawiilClassic psychedelic compounds — a group that includes psilocybin, LSD, DMT and mescaline — induce profound alterations in perception, cognition and emotion. These substances have captured scientific and clinical attention, partly because guided treatment with psychedelics can provide rapid and long-lasting relief for people with certain psychiatric conditions, such as major depressive disorder1. However, despite the promise that psychedelics show in the clinic, the neural mechanisms that link their acute effects to lasting therapeutic benefits are poorly understood. Human neuroimaging studies have consistently shown that psychedelics disrupt the brain’s intrinsic functional organization, producing a ‘desynchronized’ state2. Writing in Nature, Stoliker et al.3 provide a compelling new perspective: rather than simply making brain activity noisier, psilocybin reorganizes neural dynamics in relation to a person’s surrounding world.
doi: https://doi.org/10.1038/d41586-026-02377-9
References Goodwin, G. M. et al. N. Engl. J. Med. 387, 1637–1648 (2022). Carhart-Harris, R. L. Brain https://doi.org/10.1093/brain/awag206 (2026). Stoliker, D. et al. Nature https://doi.org/10.1038/s41586-026-10910-z (2026). Fox, M. D. & Raichle, M. E. Nature Rev. Neurosci. 8, 700–711 (2007). Girn, M. et al. Nature Methods 32, 1543–1554 (2026). Avram, M. et al. Mol. Psychiatry 30, 1297–1307 (2025). Siegel, J. S. et al. Nature 632, 131–138 (2024). Daws, R. E. et al. Nature Med. 28, 844–851 (2022). Mertens, L. J. et al. JAMA Psychiatry 83, 448–460 (2026). Lyons, T. et al. Nature Commun. 17, 3977 (2026). Avram, M. et al. Cell Rep. Med. 7, 102791 (2026). Download references
Competing Interests S.B. is the secretary (an unpaid, voluntary position) for the German Society for Psychedelic Research and Therapy (DGPFT) e.V..
Related Articles
Subjects